Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
A Novel Approach for Treatment Patients with Multiple Sclerosis by Using DNA Polymerase
Sherif Salah*
Consultant of Clinical Pathology/Faculty of Vet Medicine, University of Cairo, Egypt
- *Corresponding Author:
- Sherif Salah Salah
Department of Clinical Pathology
Cairo University, Cairo, Egypt
Tel: 01005218981
E-mail: sherif64@mail.com
Received date: April 27, 2016; Accepted date: May 03, 2016; Published date: May 10, 2016
Citation: Salah S (2016) A Novel Approach for Treatment Patients with Multiple Sclerosis by Using DNA Polymerase. J Alzheimers Dis Parkinsonism 6:235. doi:10.4172/2161-0460.1000235
Copyright: © 2016 Salah S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Introduction: Multiple sclerosis (MS) is a complex inflammatory demyelinating disease of the central nervous system (CNS) with both genetic and environmental contributing factors. In recent years, increasing evidence has pointed to the potential role of fibrinolysis in the pathogenesis of MS. Based on hypotheses describing the aggressive autoimmune responses observed in MS patients, a result of impaired which results in impairment between t-PA and PA1-1 which are a key molecules in both fibrinolysis and extracellular proteolysis.
Aim of the study: The aim of the present study is to investigate the therapeutic potential of polymerase enzyme in modulating the changes occurring between levels of Tissue- type plasminogen activator (t-PA) and its inhibitor (PAI-1) in patients with multiple sclerosis.
Patients and methods: A pilot study was carried out on a total of twenty-one patients (17 females, 4 males; aged 22-46 years) with demyelination suggestive of MS and clinically silent T2 brain lesions on magnetic resonance imaging (MRI). All of the examined patients showed the same clinical symptoms of MS and consented to take the novel therapy in the form of subcutaneous injection of 0.1 cc of DNA polymerase enzyme twice daily for 24 weeks. At the beginning of this study and at the end of therapy the plasmatic levels of PAI-1and t-PA were measured by ELISA and their values were expressed in ng/mg of protein.
Results: All patients showed a significant association between the decreased levels of PAI-1and the disappearance of annualized relapse rate (ARR), disability progression, and magnetic resonance imaging (MRI) activity.
Conclusion: From this study we conclude that DNA polymerase is viable therapeutic option in patients with MS.
